SK18702000A3 - SPâSOB PRÖPRAVY EXTRAKTOV HYPERICUM PERFORATUM, EXTRAKTY Z HYPERICUM PERFORATUM, FARMACEUTICKí PROSTRIEDOK S ICH OBSAHOM A ICH POU¦ITIE - Google Patents
SPâSOB PRÖPRAVY EXTRAKTOV HYPERICUM PERFORATUM, EXTRAKTY Z HYPERICUM PERFORATUM, FARMACEUTICKí PROSTRIEDOK S ICH OBSAHOM A ICH POU¦ITIE Download PDFInfo
- Publication number
- SK18702000A3 SK18702000A3 SK1870-2000A SK18702000A SK18702000A3 SK 18702000 A3 SK18702000 A3 SK 18702000A3 SK 18702000 A SK18702000 A SK 18702000A SK 18702000 A3 SK18702000 A3 SK 18702000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- extracts
- hypericum perforatum
- process according
- acid
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 235000017309 Hypericum perforatum Nutrition 0.000 title claims abstract description 29
- 244000141009 Hypericum perforatum Species 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims description 11
- 238000009472 formulation Methods 0.000 title description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 claims description 16
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 claims description 16
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 229940005608 hypericin Drugs 0.000 claims description 11
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 claims description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 229930003944 flavone Natural products 0.000 claims description 5
- 150000002213 flavones Chemical class 0.000 claims description 5
- 235000011949 flavones Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 150000001298 alcohols Chemical class 0.000 abstract description 2
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 239000002035 hexane extract Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 3
- 241000546188 Hypericum Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical class O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 1
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 235000020759 St. John’s wort extract Nutrition 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000695 effect on serotonin Effects 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical class O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012476 oxidizable substance Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000003163 serotoninmimetic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- -1 sulfur amino acids Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000007964 xanthones Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Extraction Or Liquid Replacement (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI001311A IT1301678B1 (it) | 1998-06-10 | 1998-06-10 | Estratti di hypericum perforatum e formulazioni che li contengono. |
| PCT/EP1999/003881 WO1999064027A1 (en) | 1998-06-10 | 1999-06-04 | Extracts of hypericum perforatum and formulations containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK18702000A3 true SK18702000A3 (sk) | 2001-09-11 |
Family
ID=11380209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1870-2000A SK18702000A3 (sk) | 1998-06-10 | 1999-06-04 | SPâSOB PRÖPRAVY EXTRAKTOV HYPERICUM PERFORATUM, EXTRAKTY Z HYPERICUM PERFORATUM, FARMACEUTICKí PROSTRIEDOK S ICH OBSAHOM A ICH POU¦ITIE |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6428820B2 (it) |
| EP (1) | EP1089746A1 (it) |
| JP (1) | JP2002517455A (it) |
| KR (1) | KR20010052636A (it) |
| CN (1) | CN1304314A (it) |
| AU (1) | AU754161B2 (it) |
| BR (1) | BR9910941A (it) |
| CA (1) | CA2334625A1 (it) |
| HU (1) | HUP0102213A3 (it) |
| IL (1) | IL140150A0 (it) |
| IT (1) | IT1301678B1 (it) |
| MX (1) | MXPA00012178A (it) |
| NO (1) | NO20006229L (it) |
| PL (1) | PL344695A1 (it) |
| SK (1) | SK18702000A3 (it) |
| WO (1) | WO1999064027A1 (it) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2159270B1 (es) | 2000-03-06 | 2002-04-01 | Asac Compania De Biotecnologia | Oleorresina de hypericum perforatum l., procedimiento de obtencion y usos. |
| AT408835B8 (de) * | 2000-05-23 | 2002-07-25 | Andreas Dipl Ing Dr Kubin | Präparation von hypericin gebunden an polyvinylpyrrolidon (pvp) verschiedenen polymerisations- und vernetzungsgrades |
| DE10213571A1 (de) * | 2002-03-26 | 2003-10-23 | Lichtwer Pharma Ag | Pflanzenextrakte und deren Anwendung |
| US20060115555A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplements containing xanthone extracts |
| US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
| PT103377B (pt) * | 2005-11-02 | 2008-04-15 | Ineti Inst Nac De Engenharia E | Extratos de espécies de hypericum l. para utilização no tratamento de tuberculose persistente |
| FR2908996A1 (fr) * | 2005-11-25 | 2008-05-30 | R & D Pharma | Nouveau procede d'extraction de principes actifs et l'utilisation de ceux-ci en therapeutique |
| FR2908997B1 (fr) * | 2005-11-25 | 2014-03-14 | R Et D Pharma | Nouvelles compositions therapeutiques et le procede de production des principes actifs |
| US20080267899A1 (en) * | 2007-04-30 | 2008-10-30 | Mr. Hamit Leskaj | Plant extract composition for hair growth |
| ITMI20080316A1 (it) * | 2008-02-27 | 2009-08-28 | Aboca Spa | Impiego di estratti di hypericum perforatum nel trattamento del dolore neuropatico |
| US7974647B2 (en) * | 2008-05-16 | 2011-07-05 | Mediatek Inc. | Mobile apparatus and method of timing synchronization |
| CN101744890A (zh) * | 2008-12-08 | 2010-06-23 | 上海四埃美微科技有限公司 | 一种贯叶连翘提取物中金丝桃素的精制的方法 |
| RU2541134C2 (ru) * | 2012-12-06 | 2015-02-10 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Дагестанский Государственный Технический Университет" (Дгту) | Способ получения сухого растительного экстракта зверобоя продырявленного |
| CN109044999A (zh) * | 2018-10-15 | 2018-12-21 | 上海市第六人民医院 | 贯叶金丝桃素在制备促进白色脂肪棕色化并且提高棕色脂肪活性的药物中的用途 |
| CN114053752A (zh) * | 2021-11-18 | 2022-02-18 | 西安天一生物技术股份有限公司 | 一种利用溶剂脱除贯叶连翘提取物中苯并芘的方法 |
| CN118724815A (zh) * | 2024-06-20 | 2024-10-01 | 中日友好医院(中日友好临床医学研究所) | 一种间苯三酚类化合物Hyperforidiol E及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239959A1 (de) * | 1992-11-27 | 1994-06-01 | Schwabe Willmar Gmbh & Co | Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung |
| DE19646977A1 (de) * | 1995-09-29 | 1998-01-15 | Schwabe Willmar Gmbh & Co | Stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen |
| DE19818001C1 (de) * | 1998-04-22 | 1999-08-05 | Plantamed Arzneimittel Gmbh | Verfahren zur schonenden Gewinnung von Extraktfraktionen aus Hypericum, diese enthaltende pharmazeutische Zubereitungen und Verwendung derselben |
-
1998
- 1998-06-10 IT IT1998MI001311A patent/IT1301678B1/it active IP Right Grant
-
1999
- 1999-06-04 HU HU0102213A patent/HUP0102213A3/hu unknown
- 1999-06-04 WO PCT/EP1999/003881 patent/WO1999064027A1/en not_active Ceased
- 1999-06-04 JP JP2000553095A patent/JP2002517455A/ja active Pending
- 1999-06-04 IL IL14015099A patent/IL140150A0/xx unknown
- 1999-06-04 SK SK1870-2000A patent/SK18702000A3/sk unknown
- 1999-06-04 BR BR9910941-7A patent/BR9910941A/pt not_active IP Right Cessation
- 1999-06-04 CA CA002334625A patent/CA2334625A1/en not_active Abandoned
- 1999-06-04 MX MXPA00012178A patent/MXPA00012178A/es unknown
- 1999-06-04 AU AU45070/99A patent/AU754161B2/en not_active Ceased
- 1999-06-04 KR KR1020007013865A patent/KR20010052636A/ko not_active Withdrawn
- 1999-06-04 EP EP99927878A patent/EP1089746A1/en not_active Withdrawn
- 1999-06-04 CN CN99807127A patent/CN1304314A/zh active Pending
- 1999-06-04 PL PL99344695A patent/PL344695A1/xx unknown
-
2000
- 2000-11-30 US US09/725,938 patent/US6428820B2/en not_active Expired - Fee Related
- 2000-12-07 NO NO20006229A patent/NO20006229L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20006229D0 (no) | 2000-12-07 |
| CN1304314A (zh) | 2001-07-18 |
| CA2334625A1 (en) | 1999-12-16 |
| PL344695A1 (en) | 2001-11-19 |
| BR9910941A (pt) | 2001-03-06 |
| MXPA00012178A (es) | 2003-09-25 |
| IL140150A0 (en) | 2002-02-10 |
| US6428820B2 (en) | 2002-08-06 |
| IT1301678B1 (it) | 2000-07-07 |
| JP2002517455A (ja) | 2002-06-18 |
| NO20006229L (no) | 2000-12-07 |
| EP1089746A1 (en) | 2001-04-11 |
| KR20010052636A (ko) | 2001-06-25 |
| WO1999064027A1 (en) | 1999-12-16 |
| AU754161B2 (en) | 2002-11-07 |
| HUP0102213A2 (hu) | 2002-03-28 |
| HUP0102213A3 (en) | 2002-12-28 |
| AU4507099A (en) | 1999-12-30 |
| US20010000326A1 (en) | 2001-04-19 |
| ITMI981311A1 (it) | 1999-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK18702000A3 (sk) | SPâSOB PRÖPRAVY EXTRAKTOV HYPERICUM PERFORATUM, EXTRAKTY Z HYPERICUM PERFORATUM, FARMACEUTICKí PROSTRIEDOK S ICH OBSAHOM A ICH POU¦ITIE | |
| Asgarpanah et al. | Phytochemistry and pharmacological properties of Ruta graveolens L | |
| EP1569672B1 (fr) | Utilisation d'un extrait de centella asiatica riche en madecassoside et en terminoloside | |
| Owoyele et al. | Anti-inflammatory and analgesic activities of leaf extracts of Landolphia owariensis | |
| RU2438692C2 (ru) | Растительный экстракт и его терапевтическое применение | |
| Kanmaz et al. | Volatiles, phenolic compounds and bioactive properties of essential oil and aqueous extract of purple basil (Ocimum basilicum L.) and antidiabetic activity in streptozotocin-induced diabetic Wistar rats | |
| Zebua et al. | Hypoglicemic activity of gambier (Uncaria gambir robx.) drinks in alloxan-induced mice | |
| FR2495936A1 (fr) | Composition pharmaceutique a usage topique a base d'un extrait total d'hedysarum fructescens willd | |
| Kumar et al. | Central nervous system activity of acute administration of ethanol extract of Punica granatum L. seeds in mice | |
| Majumder et al. | Antioxidant and anti-diabetic activities of the methanolic extract of Premna integrifolia bark | |
| Rattmann et al. | Nitric oxide-dependent vasorelaxation induced by extractive solutions and fractions of Maytenus ilicifolia Mart ex Reissek (Celastraceae) leaves | |
| Rangra et al. | In vivo antiinflammatory potential of leaf extracts of Acacia auriculiformis Benth | |
| Raut et al. | Pharmacognosti c and pharmacological aspects on Tabernaemontana divaricata plant | |
| US6656510B2 (en) | Hyperforin derivatives, use thereof and formulations containing them | |
| EP0317453B1 (fr) | Compositions médicamenteuses à base de flavonoides et de saponines extraits de chrysanthellum, leur procédé de préparation et applications thérapeutiques | |
| KR100987303B1 (ko) | 오리나무 유래 디아릴헵타노이드계 화합물을 포함하는 항산화 및 간보호용 조성물 | |
| Omotoso et al. | Assessment of histo-reparative effect of methanolic extract of Camellia sinensis in rat model of Lead-induced testicular damage | |
| AU2006312678B2 (en) | Extracts from the bark of corynanthe species, use thereof, and medicaments, dietary products, and pharmaceutical preparations containing said extracts | |
| CZ20004563A3 (cs) | Extrakty z Hypericum perforatum a přípravky je obsahující | |
| HK1036760A (en) | Extracts of hypericum perforatum and formulations containing them | |
| KR100752952B1 (ko) | 야콘 또는 그 추출물을 포함한 약학적 조성물 | |
| Ugwu et al. | Preliminary Standardization of Fadogia cienkowskii Schweinf (Rubiaceae) Leaves and Evaluation of the Anti-inflammatory Activity of the Methanol Extract. | |
| Yelchuri et al. | Assessment of antidiabetic activity of ethanolic extracts of Gyrocarpus asiaticus Willd bark against Streptozotocin induced diabetes in rats | |
| OA21234A (fr) | Médicament traditionnel amélioré antipaludique à base des graines de Picralima nitida et procédé de fabrication. | |
| Gupta et al. | Evaluation Of Antihyperlipidemic And Phytochemical Screening Of Vitex Trifolia Linn And Corchorus Trilocularis In Rat |